Impact of pre‐lung transplant statin use on the development of primary graft dysfunction

Yuenger, Valerie; January, Spenser E.; Fester, K.A.; McCloskey, Michele; Hachem, Ramsey R.

doi:10.1002/phar.2770

Pharmacotherapy

2023

DOI: 10.1002/phar.2770

|View full text |Cite

Impact of pre‐lung transplant statin use on the development of primary graft dysfunction

Valerie Yuenger

Spenser E. January

K.A. Fester

et al.

Abstract: Primary graft dysfunction (PGD) is an acute lung injury occurring within 72 h of lung transplantation. The International Society for Heart and Lung Transplantation (ISHLT) defines diagnostic criteria, which consists of the presence of pulmonary infiltrates on imaging and the ratio of arterial oxygen partial pressure (PaO 2 ) to fractional inspired oxygen (FiO 2 ), or the P/F ratio. The P/F ratio is evaluated at

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Population Pharmacokinetic and Pharmacodynamic of Atorvastatin in Chinese Lung Transplant Recipients

Zhang,

Du,

Qin

et al. 2024

The Journal of Clinical Pharma

View full text Add to dashboard Cite

Atorvastatin is a widely prescribed cholesterol‐lowering drug that inhibits 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase to reduce lipid levels. This study aimed to establish a population pharmacokinetic and pharmacodynamic model for atorvastatin in Chinese lung transplant recipients (LTRs), particularly those using voriconazole (VOR) and with different genotypes. It evaluated precise dosing regimens and analyzed the correlation between atorvastatin exposure and clinical outcomes. A nonlinear mixed‐effects model was used for the population pharmacokinetic/pharmacodynamic (PK/PD) analysis. A one‐compartment population PK model was developed, incorporating VOR, SLCO2A1 rs76906503, and SLC22A8 rs2187383 to assess apparent clearance and volume of distribution. LDL‐C was modeled as a biomarker to evaluate atorvastatin efficacy. A Monte Carlo simulation was conducted to assess various dosing schemes and the effects of different covariates on achieving the target LDL concentration. The correlation between atorvastatin exposure and clinical outcomes was also evaluated. Results indicated that the average probability of target attainment for optimal dosing regimens across various covariate results exceeded 45.8%. Dosages of 10, 20, and 40 mg were deemed suitable for LTRs. A lower dose was recommended for LTRs taking VOR or with mutant‐type genotypes to avoid overexposure and adverse reactions. The population PK/PD model offers valuable guidance for evaluating atorvastatin dosing regimens in clinical settings, particularly for LTRs using VOR and those with different genotypes.

show abstract

Population Pharmacokinetic and Pharmacodynamic of Atorvastatin in Chinese Lung Transplant Recipients

Zhang,

Du,

Qin

et al. 2024

The Journal of Clinical Pharma

View full text Add to dashboard Cite

show abstract

Impact of statin treatment and exposure on the risk of chronic allograft dysfunction in Chinese lung transplant recipients

Zhang

Wang

et al. 2023

Pulmonary Pharmacology & Therapeutics

View full text Add to dashboard Cite

Impact of Long-Term Atorvastatin Therapy on the Development of Chronic Lung Allograft Dysfunction in Patients with Azithromycin Prophylaxis after Lung Transplantation

Zhang,

Wang,

et al. 2024

Transplantation Proceedings

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Impact of pre‐lung transplant statin use on the development of primary graft dysfunction

Cited by 3 publications

References 19 publications

Population Pharmacokinetic and Pharmacodynamic of Atorvastatin in Chinese Lung Transplant Recipients

Population Pharmacokinetic and Pharmacodynamic of Atorvastatin in Chinese Lung Transplant Recipients

Impact of statin treatment and exposure on the risk of chronic allograft dysfunction in Chinese lung transplant recipients

Impact of Long-Term Atorvastatin Therapy on the Development of Chronic Lung Allograft Dysfunction in Patients with Azithromycin Prophylaxis after Lung Transplantation

Contact Info

Product

Resources

About